Literature DB >> 11090146

Enrichment of immediate-early 1 (m123/pp89) peptide-specific CD8 T cells in a pulmonary CD62L(lo) memory-effector cell pool during latent murine cytomegalovirus infection of the lungs.

R Holtappels1, M F Pahl-Seibert, D Thomas, M J Reddehase.   

Abstract

Interstitial cytomegalovirus (CMV) pneumonia is a clinically relevant complication in recipients of bone marrow transplantation (BMT). Recent data for a model of experimental syngeneic BMT and concomitant infection of BALB/c mice with murine CMV (mCMV) have documented the persistence of tissue-resident CD8 T cells after clearance of productive infection of the lungs (J. Podlech, R. Holtappels, M.-F. Pahl-Seibert, H.-P. Steffens, and M. J. Reddehase, J. Virol. 74:7496-7507, 2000). It was proposed that these cells represent antiviral "standby" memory cells whose functional role might be to help prevent reactivation of latent virus. The pool of pulmonary CD8 T cells was composed of two subsets defined by the T-cell activation marker L-selectin (CD62L): a CD62L(hi) subset of quiescent memory cells, and a CD62L(lo) subset of recently resensitized memory-effector cells. In this study, we have continued this line of investigation by quantitating CD8 T cells specific for the three currently published antigenic peptides of mCMV: peptide YPHFMPTNL processed from the immediate-early protein IE1 (pp89), and peptides YGPSLYRRF and AYAGLFTPL, derived from the early proteins m04 (gp34) and M84 (p65), respectively. IE1-specific CD8 T cells dominated in acute-phase pulmonary infiltrates and were selectively enriched in latently infected lungs. Notably, most IE1-specific CD8 T cells were found to belong to the CD62L(lo) subset representing memory-effector cells. This finding is in accordance with the interpretation that IE1-specific CD8 T cells are frequently resensitized during latent infection of the lungs and may thus be involved in the maintenance of mCMV latency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090146      PMCID: PMC112429          DOI: 10.1128/jvi.74.24.11495-11503.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Identification of a K(d)-restricted antigenic peptide encoded by murine cytomegalovirus early gene M84.

Authors:  Rafaela Holtappels; Doris Thomas; Matthias J Reddehase
Journal:  J Gen Virol       Date:  2000-12       Impact factor: 3.891

2.  Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors.

Authors:  M J Reddehase; S Jonjić; F Weiland; W Mutter; U H Koszinowski
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs.

Authors:  M J Reddehase; F Weiland; K Münch; S Jonjic; A Lüske; U H Koszinowski
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

4.  Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity.

Authors:  J L Whitton; A Tishon; H Lewicki; J Gebhard; T Cook; M Salvato; E Joly; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes.

Authors:  M J Reddehase; J B Rothbard; U H Koszinowski
Journal:  Nature       Date:  1989-02-16       Impact factor: 49.962

6.  Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes.

Authors:  D M Kranz; S Tonegawa; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

7.  In vivo replication, latency, and immunogenicity of murine cytomegalovirus mutants with deletions in the M83 and M84 genes, the putative homologs of human cytomegalovirus pp65 (UL83).

Authors:  C S Morello; L D Cranmer; D H Spector
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

8.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity.

Authors:  M J Reddehase; W Mutter; K Münch; H J Bühring; U H Koszinowski
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

9.  Is cytomegalovirus interstitial pneumonitis in transplant recipients an immunopathological condition?

Authors:  J E Grundy; J D Shanley; P D Griffiths
Journal:  Lancet       Date:  1987-10-31       Impact factor: 79.321

10.  Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection.

Authors:  M J Reddehase; U H Koszinowski
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

View more
  125 in total

1.  Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs.

Authors:  N K Grzimek; D Dreis; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

5.  B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence.

Authors:  Ramon Arens; Andrea Loewendorf; Min J Her; Kirsten Schneider-Ohrum; Geoffrey R Shellam; Edith Janssen; Carl F Ware; Stephen P Schoenberger; Chris A Benedict
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

6.  Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.

Authors:  Dan A Erkes; Guangwu Xu; Constantine Daskalakis; Katherine A Zurbach; Nicole A Wilski; Toktam Moghbeli; Ann B Hill; Christopher M Snyder
Journal:  Mol Ther       Date:  2016-06-10       Impact factor: 11.454

7.  Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

Authors:  Irena Slavuljica; Andreas Busche; Marina Babić; Maja Mitrović; Iva Gašparović; Durđica Cekinović; Elitza Markova Car; Ester Pernjak Pugel; Ana Ciković; Vanda Juranić Lisnić; William J Britt; Ulrich Koszinowski; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

8.  Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells.

Authors:  Christopher M Snyder; Kathy S Cho; Elizabeth L Bonnett; Serani van Dommelen; Geoffrey R Shellam; Ann B Hill
Journal:  Immunity       Date:  2008-10-17       Impact factor: 31.745

9.  Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens.

Authors:  Anna Lang; James D Brien; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

10.  Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice.

Authors:  Meghan R Forster; Joanne Trgovcich; Peter Zimmerman; Alexander Chang; Cortland Miller; Paul Klenerman; Charles H Cook
Journal:  Antiviral Res       Date:  2009-12-11       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.